X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (1466) 1466
Newsletter (52) 52
Newspaper Article (19) 19
Book Chapter (14) 14
Magazine Article (4) 4
Transcript (2) 2
Conference Proceeding (1) 1
Dissertation (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
liraglutide (1283) 1283
science & technology (1120) 1120
life sciences & biomedicine (1089) 1089
humans (922) 922
diabetes mellitus, type 2 - drug therapy (640) 640
type 2 diabetes (608) 608
male (584) 584
diabetes (538) 538
endocrinology & metabolism (516) 516
glucagon-like peptide 1 - analogs & derivatives (498) 498
hypoglycemic agents - therapeutic use (461) 461
female (451) 451
middle aged (356) 356
animals (340) 340
hypoglycemic agents - administration & dosage (299) 299
glucagon (294) 294
glucagon-like peptide 1 - therapeutic use (288) 288
treatment outcome (269) 269
liraglutide - therapeutic use (268) 268
insulin (258) 258
obesity (256) 256
glucose (251) 251
drug therapy (237) 237
exenatide (230) 230
adult (229) 229
aged (229) 229
liraglutide - administration & dosage (225) 225
diabetes mellitus (222) 222
hypoglycemic agents - adverse effects (220) 220
pharmacology & pharmacy (220) 220
analysis (217) 217
diabetes mellitus, type 2 - blood (215) 215
peptides (210) 210
research (210) 210
care and treatment (202) 202
hypoglycemic agents - pharmacology (197) 197
clinical trials (193) 193
dosage and administration (192) 192
blood glucose - drug effects (190) 190
diabetes therapy (181) 181
glucagon-like peptide 1 - administration & dosage (178) 178
liraglutide - pharmacology (162) 162
internal medicine (158) 158
blood glucose - metabolism (156) 156
health aspects (153) 153
body weight (151) 151
risk factors (147) 147
glucagon-like peptide 1 - pharmacology (146) 146
glucagon-like peptide-1 receptor (146) 146
glucagon-like peptide-1 receptor - agonists (146) 146
general & internal medicine (145) 145
glp-1 (144) 144
mice (144) 144
glucagon-like peptide 1 (141) 141
medicine, general & internal (140) 140
obesity - drug therapy (140) 140
peptides - therapeutic use (140) 140
abridged index medicus (136) 136
drug therapy, combination (134) 134
venoms - therapeutic use (129) 129
weight loss (126) 126
glucagon-like peptide 1 - adverse effects (124) 124
body mass index (122) 122
hypoglycemic agents (121) 121
insulin resistance (121) 121
dextrose (120) 120
glycated hemoglobin a - metabolism (120) 120
body weight - drug effects (119) 119
double-blind method (119) 119
medicine & public health (118) 118
receptors, glucagon - agonists (118) 118
weight loss - drug effects (118) 118
rodents (115) 115
liraglutide - adverse effects (113) 113
drug administration schedule (112) 112
type 2 diabetes mellitus (107) 107
hypoglycemia (103) 103
diabetes mellitus, type 2 - metabolism (101) 101
weight control (100) 100
glycated hemoglobin a - analysis (98) 98
physiological aspects (97) 97
rats (96) 96
glucagon-like peptide-1 (95) 95
patients (95) 95
diabetes mellitus, type 2 - complications (94) 94
medical research (94) 94
endocrinology (92) 92
original (92) 92
glycosylated hemoglobin (91) 91
incretins - therapeutic use (84) 84
medicine, research & experimental (83) 83
research & experimental medicine (82) 82
studies (81) 81
metformin (80) 80
blood pressure (77) 77
diabetes mellitus, type 2 - physiopathology (77) 77
dose-response relationship, drug (77) 77
hyperglycemia (77) 77
metabolism (75) 75
complications and side effects (74) 74
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (1530) 1530
Japanese (9) 9
German (8) 8
Spanish (5) 5
French (4) 4
Chinese (3) 3
Portuguese (3) 3
Czech (2) 2
Danish (1) 1
Hungarian (1) 1
Korean (1) 1
Persian (1) 1
Russian (1) 1
Swedish (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Scientific reports, ISSN 2045-2322, 01/2016, Volume 6, Issue 1, pp. 18904 - 18904
A meta-analysis was conducted to assess the clinical efficacy and safety of dulaglutide in patients with type 2 diabetes mellitus (T2DM). Medline, Embase,... 
Science & Technology - Other Topics | Multidisciplinary Sciences | Science & Technology | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Glycated Hemoglobin A - metabolism | Humans | Body Weight - drug effects | Immunoglobulin Fc Fragments - administration & dosage | Insulin - blood | Metformin - adverse effects | Peptides - administration & dosage | Insulin Glargine - administration & dosage | Hypoglycemic Agents - administration & dosage | Hypoglycemia - physiopathology | Patient Safety | Venoms - administration & dosage | Hypoglycemia - blood | Metformin - administration & dosage | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Sitagliptin Phosphate - administration & dosage | Insulin Glargine - adverse effects | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Diabetes Mellitus, Type 2 - physiopathology | Hypoglycemia - etiology | Liraglutide - adverse effects | Liraglutide - administration & dosage | Blood Glucose - metabolism | Diabetes Mellitus, Type 2 - drug therapy | Hypoglycemic Agents - adverse effects | Peptides - adverse effects | Sitagliptin Phosphate - adverse effects | Diabetes mellitus | Body weight | Clinical trials | Body weight loss | Diabetes | Metformin | Hypoglycemia | Insulin | Index Medicus
Journal Article
Journal Article
Diabetes, obesity & metabolism, ISSN 1462-8902, 04/2017, Volume 19, Issue 4, pp. 524 - 536
Aims To compare efficacy and safety of glucagon‐like peptide‐1 receptor agonists (GLP‐1RAs) in people with type 2 diabetes. Materials and methods We... 
GLP‐1 analogue | type 2 diabetes | network meta‐analysis | systematic review | network meta-analysis | GLP-1 analogue | Life Sciences & Biomedicine | Endocrinology & Metabolism | Science & Technology | Glucagon-Like Peptide 1 - administration & dosage | Recombinant Fusion Proteins - adverse effects | Glucagon-Like Peptides - administration & dosage | Humans | Middle Aged | Glycated Hemoglobin A - drug effects | Male | Immunoglobulin Fc Fragments - administration & dosage | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Venoms - administration & dosage | Female | Hypoglycemia - chemically induced | Glucagon-Like Peptides - analogs & derivatives | Immunoglobulin Fc Fragments - adverse effects | Recombinant Fusion Proteins - administration & dosage | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Treatment Outcome | Randomized Controlled Trials as Topic | Blood Glucose - drug effects | Glucagon-Like Peptides - adverse effects | Diabetes Mellitus, Type 2 - blood | Liraglutide - adverse effects | Incretins - adverse effects | Liraglutide - administration & dosage | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Glucagon-Like Peptide-1 Receptor - agonists | Incretins - administration & dosage | Peptides - adverse effects | Type 2 diabetes | Glycosylated hemoglobin | Glucagon | Analysis | Diabetes therapy | Hypoglycemia | Diabetes | Systematic review | Evidence-based medicine | Index Medicus
Journal Article
Journal Article
Journal Article
Journal Article
Journal Article
The Lancet (British edition), ISSN 0140-6736, 2006, Volume 368, Issue 9548, pp. 1696 - 1705
Glucagon-like peptide 1 (GLP-1) is a gut-derived incretin hormone that stimulates insulin and suppresses glucagon secretion, inhibits gastric emptying, and... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Triazoles - administration & dosage | Triazoles - adverse effects | Glucagon-Like Peptide 1 - administration & dosage | Humans | Pyrazines - administration & dosage | Glucagon-Like Peptide 1 - biosynthesis | Dipeptidyl Peptidase 4 | Glucagon-Like Peptide 1 - physiology | Pyrazines - therapeutic use | Adenosine Deaminase Inhibitors | Peptides - administration & dosage | Hypoglycemic Agents - administration & dosage | Adamantane - therapeutic use | Pyrrolidines | Venoms - administration & dosage | Nitriles | Sitagliptin Phosphate | Adamantane - administration & dosage | Adamantane - adverse effects | Adamantane - analogs & derivatives | Triazoles - therapeutic use | Glucagon-Like Peptide 1 - classification | Hypoglycemic Agents - therapeutic use | Receptors, Glucagon - agonists | Drug Administration Schedule | Glucagon-Like Peptide 1 - analogs & derivatives | Venoms - adverse effects | Glycoproteins - antagonists & inhibitors | Clinical Trials as Topic | Glucagon-Like Peptide-1 Receptor | Dipeptidyl-Peptidase IV Inhibitors | Pyrazines - adverse effects | Venoms - therapeutic use | Diabetes Mellitus, Type 2 - drug therapy | Glucagon-Like Peptide 1 - adverse effects | Hypoglycemic Agents - adverse effects | Liraglutide | Peptid